XNK partners with KI on Phase II study in MM with support from Sanofi

On February 26, 2021 XNK Therapeutics AB ("XNK") reported that it is entering into a joint Phase II clinical study to treat patients with multiple myeloma using XNK’s leading drug candidate in combination with Sanofi’s anti-CD38 antibody Sarclisa (isatuximab) (Press release, CellProtect Nordic Pharmaceuticals, FEB 26, 2021, View Source [SID1234575731]). XNK and Sanofi are both collaborative partners within NextGenNK Competence Center coordinated by Karolinska Institutet.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The investigator-initiated Phase II study is made possible by the three parties’ contributions to the trial. XNK will provide its novel autologous NK cell-based product to the study set to take place at the Karolinska University Hospital in Stockholm, Sweden.

"Performing this Phase II study together with Karolinska Institutet is an important step for XNK in its ambition to combat multiple myeloma," said Johan Liwing, CEO of XNK Therapeutics. "Combining our efforts together with the present partners highlights just how far XNK has progressed with its patented technology platform."

"We really look forward towards conducting this exciting clinical trial including partnering with XNK Therapeutics," said Hareth Nahi, Associate Professor at KI.

The study ISA-HC-NK (EudraCT: 2020-000994-26) compares XNK’s leading drug candidate combined with isatuximab vs isatuximab as a consolidation treatment following autologous stem cell transplantation in patients with newly diagnosed multiple myeloma.

XNK is a collaborative partner within NextGenNK, a recently established Competence Center for the development of next-generation NK cell-based cancer immunotherapies coordinated by Karolinska Institutet and supported by Sweden’s Innovation Agency (Vinnova).